Bio Essence Creates 10,000-Vote Preferred Class via Written Consent
BIOE has more than doubled off its 52-week low of $0.051.
Summary
Bio Essence shareholders holding 63.93% of the common stock approved, by written consent, a charter amendment giving each future preferred share 10,000 votes. No preferred stock is outstanding yet, but the new class lets insiders hold or transfer control without buying common shares.
Key Events · Corporate Governance and Compliance · BIOE
-
Super-Voting Preferred Class Approved
Board and holders of 63.93% of common stock consented in writing on October 19, 2026 to amend the charter so each preferred share carries 10,000 votes versus one vote per common share.
-
No Preferred Shares Outstanding Yet
The company states there are currently no preferred shares issued or outstanding; the 10,000,000 authorized preferred shares are a future instrument, so no voting power has shifted as of this filing.
-
Control Mechanism, Not Common Dilution
Management says the amendment lets it later issue shares to a party that would maintain or transition control without diluting common shareholders. Authorized capital is 100,000,000 common and 10,000,000 preferred shares against 53,809,000 common shares outstanding.
-
Effective After 20-Day Notice Period
The amendment takes effect only after the Rule 14c 20-day period and filing with the California Secretary of State; the information statement is expected to be mailed on or about November 20, 2026.
Analysis · BIOE · Life Sciences
Two insiders who already control 63.93% of the common stock have approved a charter amendment creating a preferred class where each share carries 10,000 votes. No preferred shares exist yet, so nothing changes today — but the company can later hand a small number of preferred shares to a chosen holder and lock in or transfer control while telling common holders they were not diluted. For a company that previously disclosed going-concern doubts and ineffective internal controls, a mechanism that concentrates voting power outside the common shares is a governance change investors should price in. The amendment cannot take effect until at least 20 days after the definitive information statement is mailed, expected around November 20, 2026.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29.1% of the 1524 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIOE was trading at $0.42 on OTC in the Life Sciences sector, with a market capitalization of approximately $22.6M. The 52-week trading range was $0.05 to $10.81. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.